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Subthalamic and pallidal deep brain stimulation for
Parkinson’s disease—meta-analysis of outcomes
M. Lenard Lachenmayer 1✉, Melina Mürset1, Nicolas Antih2, Ines Debove1, Julia Muellner 1, Maëlys Bompart2, Janine-Ai Schlaeppi3,
Andreas Nowacki3, Hana You1, Joan P. Michelis1, Alain Dransart2, Claudio Pollo3, Guenther Deuschl4 and Paul Krack1
Although deep brain stimulation (DBS) of the globus pallidus internus (GPi) and the subthalamic nucleus (STN) has become an
established treatment for Parkinson’s disease (PD), a recent meta-analysis of outcomes is lacking. To address this gap, we performed
a meta-analysis of bilateral STN- and GPi-DBS studies published from 1990-08/2019. Studies with ≥10 subjects reporting Unified
Parkinson’s Disease Rating Scale (UPDRS) III motor scores at baseline and 6–12 months follow-up were included. Several outcome
variables were analyzed and adverse events (AE) were summarized. 39 STN studies (2035 subjects) and 5 GPi studies (292 subjects)
were eligible. UPDRS-II score after surgery in the stimulation-ON/medication-OFF state compared to preoperative medication-OFF
state improved by 47% with STN-DBS and 18.5% with GPi-DBS. UPDRS-III score improved by 50.5% with STN-DBS and 29.8% with
GPi-DBS. STN-DBS improved dyskinesia by 64%, daily OFF time by 69.1%, and quality of life measured by PDQ-39 by 22.2%, while
Levodopa Equivalent Daily Dose (LEDD) was reduced by 50.0%. For GPi-DBS information regarding dyskinesia, OFF time, PDQ-39
and LEDD was insufficient for further analysis. Correlation analysis showed that preoperative L-dopa responsiveness was highly
predictive of the STN-DBS motor outcome across all studies. Most common surgery-related AE were infection (5.1%) and intracranial
hemorrhage (3.1%). Despite a series of technological advances, outcomes of modern surgery are still comparable with those of the
early days of DBS. Recent changes in target selection with a preference of GPi in elderly patients with cognitive deficits and more
psychiatric comorbidities require more published data for validation.
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INTRODUCTION
The first implantation of deep brain electrodes for tremor in
Parkinson’s disease (PD) by Alim-Louis Benabid in the late 1980s in
the thalamic ventral intermediate nucleus1 paved the way for the
worldwide application of deep brain stimulation (DBS) in PD.
Despite an initial lack of randomized controlled studies, DBS of the
subthalamic nucleus (STN) or the internal part of the globus
pallidus (GPi) quickly became a well accepted therapy for
advanced PD with motor complications due to its convincing
effect on motor symptoms, shown by smaller and uncontrolled
studies2–9 and a highly quoted and influential meta-analysis by
Kleiner-Fisman and colleagues10. Since then, the field of DBS has
undergone important technical progress, and the efficacy and
safety of bilateral STN- and GPi-DBS has been underlined by large
randomized controlled trials (RCT)11–18 and many additional
uncontrolled studies, while the choice of the best target remains
a matter of controversial debate. This is partly explained by the fact
that the results of the existing RCTs are difficult to compare due to
their different primary outcomes such as quality of life13,15,17, time
in ON without dyskinesia measured with patient diaries14,16, motor
symptoms (UPDRS-III)11,12, and functional health measured with a
composite score for cognitive, mood, and behavioral effects18.
Fortunately, most of the RCTs also use some common scales either
as primary or secondary outcomes. Importantly, all studies use the
UPDRS, but when comparing UPDRS-III (whether primary or
secondary endpoint), outcomes are highly variable across pub-
lished randomized controlled studies.
Although several meta-analyses have been published in recent
years, these focused either only on the outcome of specific
symptoms or on RCTs19–21 and therefore include only a limited
number of patients. Due to the different endpoints of the studies, the
inconsistent reporting of symptoms such as dyskinesias or missing
important outcome parameters, such as quality of life, these meta-
analyses had to be basically limited to an analysis of motor outcome
(UPDRS III) as a common secondary endpoint. Ultimately, both RCTs
and previous meta-analyses leave many questions unanswered
because of the aforementioned limitations. Our meta-analysis
represents the first since the work of Kleiner-Fisman et al.10 to
include the majority of available STN and GPi studies, allowing not
only to add analysis of published outcomes from the last 15 years,
but also maximizing the number of subjects included, and analyzing
multiple outcome parameters simultaneously.
RESULTS
Literature review
As shown in Supplementary Fig. 1, the literature search identified
256 original citations. Sixty-one articles were selected according to
the inclusion criteria. Twenty-seven contributed to both safety and
efficacy, 20 contributed to safety analysis only, and 12 contributed
to efficacy analysis only. A detailed list of the corresponding
articles is provided in Supplementary Table 1. Thirty-four articles
met efficacy inclusion criteria, to which five additional articles,
identified by P.K. and L.L., were added. These historical papers (for
more detail see supplementary material) were added to facilitate
the understanding of the existing literature without any relevant
change in the statistical results. After this process, 39 STN
studies2,3,11–13,15–18,22–51 involving 2035 subjects with follow-up
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data (T1) for 1747 subjects and 5 GPi studies2,11,12,18,30 with
292 subjects (n at T1= 291) were available for efficacy outcome
analysis. For safety, 47 articles reporting on a total of 2818 enrolled
subjects met the inclusion criteria.
Patient characteristics
Detailed patient characteristics and demographic information are
shown in Supplementary Table 2. Study sample sizes (some
papers reporting outcomes of both STN and GPi DBS) ranged from
10 to 299 (median [range]= 33) and follow-up time considered for
this analysis spanned from 6 months to 2 years (weighted mean,
13.1 ± 5.9 months). The weighted mean age at surgery was 59.1 ±
2.9 years (range of means, 50.7–66.7). Weighted average disease
duration prior to surgery was 12.2 ± 2.1 years (range of means,
7.3–19.0). Compared to the period covered by Kleiner-Fisman et al.
(1993–2005)10, subjects of STN studies since 2005 were less
affected at baseline based on UPDRS-II and -III scores (Table 1 and
Supplementary Table 3).
Analyses of heterogeneity and bias
Cochran’s Q test revealed statistically significant evidence for
heterogeneity between STN studies in the datasets collected for
UPDRS-II and -III score (P < 0.0001), dyskinesia (P < 0.0013), daily
OFF time, LEDD (P < 0.0001), and for improvement of PDQ-39 SI
(P= 0.0008). Between the GPi studies, there was no significant
evidence of heterogeneity for UPDRS-II (P= 0.5916) and -III (P=
0.4321) scores, possibly due to the small sample size, while the
information for dyskinesia, daily OFF time, PDQ-39 SI, and LEDD
was insufficient for further analysis.
Funnel plots and Egger’s regression test revealed statistically
significant asymmetrical distribution only for the PDQ-39 outcome
with STN-DBS (P= 0.0028) (Supplemantary Fig. 2 and Supplemen-
tary Table 4), which is due to a variation of the effect observed in
smaller studies because of their sample size and might indicate
publication bias.
UPDRS-II
Twenty-four STN-DBS studies with a total of 1346 subjects
reported an estimated decrease in total UPDRS-II score at
follow-up in the stimulation-ON/medication-OFF state compared
with the preoperative OFF-medication state of 10.4 points (95% CI:
8.3–12.6; Fig. 1), equivalent to a 47% (95% CI: 37.4–56.7%)
reduction. The extent of this decrease in UPDRS-II score showed a
dose–response relationship with preoperative response to the
L-Dopa challenge (Supplementary Fig. 3). Compared to the period
covered by Kleiner-Fisman et al. (1993–2005)10, the STN studies
since 2005 have shown a slightly lower response of UPDRS-II to
DBS (49.9% vs. 40.9%, Table 1 and Supplementary Table 3).
For GPi, three studies with a total of 227 subjects were reporting
a decrease in UPDRS-II scores in medication-OFF condition of 3.6
points (95% CI: 2.4–4.7), equivalent in percentage to a change of
18.5% (95% CI: 12.6–24.4%; difference between postoperative
stimulation-ON/medication-OFF state and preoperative OFF-
medication state; Table 1 and Fig. 2).
UPDRS-III
Thirty-eight STN studies comprising 1859 subjects reported
change in UPDRS-III score and estimate of standard error. The
estimated decrease in UPDRS-III score at follow-up compared to
baseline was 22.1 points (95% CI: 19.9–24.3; Fig. 3), equivalent to a
50.5% (95% CI: 45.6–55.5%) reduction. The magnitude of decrease
in UPDRS-III with STN stimulation showed a dose–response
relationship with preoperative response to the L-Dopa challenge
(Fig. 4). Since 2005, studies have shown a slightly lower response
of UPDRS-III to STN-DBS compared to the period covered by
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Table 3). According to our literature search criteria, only five GPi
studies with 289 subjects were available, which showed a
decrease in UPDRS-III score after surgery of 13.0 points (95% CI:
10.7–15.4; Fig. 5), equivalent to a reduction of 29.8%.
Dyskinesia
Data for dyskinesias were very heterogeneous between studies,
due to use of different rating scales. However, conversion of mean
study scores to percentages relative to their respective scales
allowed for comparison. For this purpose, only scales that provide
an overall assessment of dyskinesias such as UPDRS-IV (item 32 to
35)52, the Abnormal Involuntary Movement Scale53, and the
Marconi Dyskinesia Rating Scale54 were used. Patient diaries and
individual items of the UPDRS IV could not be included as these
assess either only the duration or the severity of dyskinesias and
therefore do not allow such a conversion. For fourteen STN studies
with 950 subjects, the average reduction in dyskinesia at follow-up
could be determined and was 64.0% (95% CI: 56.4%–71.5%; Fig.
6A). For GPi-DBS there was a weighted mean improvement of
39.7% per Obeso et al.2 (n= 38) and Odekerken et al.18 (n= 62).
Since only one of the included GPi studies2 provided the required
data quality with standard deviation, a pooled estimate could not
be performed.
Daily OFF time
Only six STN studies with 185 subjects provided information on
the change in daily OFF time (item 39 of UPDRS-IV or patient
diaries) and the estimation of the standard error. After converting
the average study values into percentages relative to their
respective scales, the comparison revealed an average decrease
of 69.1% (95% CI: 46.8%–91.4%; Fig. 6B), while the information for
GPi was not sufficient for further analysis.
Quality of life
Change in quality of life was assessed with the PDQ-39 SI55 in
eleven STN studies with 627 subjects. An average improvement of
the summary index score of 11.0 points (95% CI: 7.9–14.1; Fig. 7) at
follow-up (approx. 22.2% of baseline weighted mean) was
observed, while the information for GPi was not sufficient to
perform the same analysis.
Levodopa equivalent daily dose (LEDD)
Thirty-one STN studies with 1644 subjects provided information
regarding changes in LEDD with an average LEDD reduction after
surgery of 50.0% (95% CI: 45.1%–54.8%; Supplementary Fig. 4),
while the information for GPi was not sufficient to perform the
same analysis.
Fig. 1 Estimated decrease in total UPDRS II score following STN-DBS. Postoperative stimulation-ON/medication-OFF vs. preoperative OFF-
medication state: UPDRS II Mean Difference. N= number of subjects at follow-up; FU= follow-up time; CI= confidence interval; RE Model=
random-effects model.
Fig. 2 Estimated decrease in total UPDRS II score following GPi-DBS. Postoperative stimulation-ON/medication-OFF vs. preoperative OFF-
medication state: UPDRS II Mean Difference. N= number of subjects at follow-up; FU= follow-up time; CI= confidence interval; RE Model=
random-effects model.
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Adverse events (AE)
Safety data were included from forty-seven STN and four GPi
studies. The median proportion of surgery-related intracranial
hemorrhage (ICH) was 3.1% including both target structures
(3.45% for STN-DBS, 2.2% for GPi-DBS). The median proportion of
surgery-related ICH with reported permanent neurological deficits
was 1.65%. Some studies additionally distinguished ICH with
temporary deficits and asymptomatic ICH with a median
proportion of 1.0% and 2.1%, respectively. The median proportion
of surgery-related infections was 5.1%. A detailed list of the
proportions of surgery-, hardware-, disease-, stimulation-, and
therapy-related side effects is provided in Supplementary Table 5.
Fig. 3 Estimated decrease in total UPDRS-III score following STN-DBS. Postoperative stimulation-ON/medication-OFF vs. preoperative OFF-
medication state: UPDRS III Mean Difference. N= number of subjects at follow-up; FU= follow-up time; CI= confidence interval; RE Model=
random-effects model.
Fig. 4 Preoperative L-dopa response predicts STN-DBS motor outcome. Dose-response relationship between preoperative L-dopa response
and improvement in UPDRS-III after STN-DBS, considering average disease duration (color shade), study population size (circle diameter), and
randomized controlled trials (red frame). Studies reviewed indicated by first author and year of publication.
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Prediction of STN-DBS benefit
For thirty-two studies, the change in UPDRS-III score caused by
L-dopa challenge at baseline (T0) was comparable to that
achieved under STN-DBS only (medication-OFF). Graphical
representation of this analysis is presented in Fig. 4. Unfortu-
nately, the data available from our article pool for GPi-DBS did
not allow us to conduct the same analysis for this therapeutic
target.
To evaluate the possible predictive power of the pre-operative
change for post-operative results of STN-DBS, normality of the
datasets collected for both variables was evaluated through a
Shapiro–Wilk test (P= 0.6673: P= 0.2569). A Pearson correlation
test was then performed that revealed a statistically significant
correlation between UPDRS-III change at baseline upon L-dopa
challenge and UPDRS-III change (medication-OFF) after STN-DBS:
correlation coefficient= 0.689958 (P= 0.00001).
Fig. 5 Estimated decrease in total UPDRS-III score following GPi-DBS. Postoperative stimulation-ON/medication-OFF vs. preoperative OFF-
medication state: UPDRS III Mean Difference. N= number of subjects at follow-up; FU= follow-up time; CI= confidence interval; RE Model=
random-effects model.
Fig. 6 Change in motor complications following STN-DBS. Postoperative vs. preoperative state: change in mean dyskinesia severity (A) and
mean OFF time (B). N= number of subjects at follow-up; FU= follow-up time; CI= confidence interval; RE Model= random-effects model.
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Variables affecting prediction of benefit from STN-DBS
To identify factors likely to influence the quality of the prediction
made by the change in UPDRS-III score upon pre-operative L-dopa
challenge, the ratio of UPDRS-III change post-op/UPDRS-III pre-op
L-dopa (“surgical efficiency index“) was used as a proxy for
assessing the quality of a prediction (if >1, post-op benefit was
underestimated by L-dopa challenge; if <1, post-op benefit was
overestimated; if=1, perfect prediction). Correlation between this
ratio (calculated for each study) and several variables was
evaluated through a Pearson correlation test (if both datasets
followed a normal distribution) or Spearman test (if one dataset
did not follow a normal distribution).
From our correlation analysis, the average disease duration prior
to implantation (R2 «1, Supplementary Fig. 5) appears to be the
only measured preoperative variable of statistically significant
influence on the predictive power of the pre-operative L-dopa
challenge (P= 0.003) (Supplementary Table 6).
No statistically significant correlation was observed between the
motor benefit prediction ratio and any other measured individual
variable (Supplementary Table 6).
DISCUSSION
The aim of this article was to provide an updated review of the
published literature on the outcomes of bilateral STN- and GPi-
DBS for PD. According to our inclusion criteria, a majority of
studies focused on the STN (n= 39) involving 1747 subjects with
follow-up data and, to a much lesser extent, the GPi (n= 5) with
291 subjects with follow-up data. Considering that the question of
whether STN- or GPi-DBS is clinically superior is still a matter of
controversial debate, and given our efforts to minimize biases
introduced by the data retrieval and analysis method (e.g., use of
random-effects model, standardized literature search, and data
extraction protocol), the striking numerical predominance of the
STN studies over the GPi studies is very surprising. GPi is an easier
target as far as immediate postoperative management is
concerned. Unlike STN-DBS, GPi-DBS does not require fine-
tuning between stimulation intensity and medication dosage.
Unilateral surgery can be easily proposed for GPi, as there is no
deterioration of the non-operated side in relation to postoperative
medication reduction56. After the publication of the US Veterans
Administration study comparing STN versus GPi-DBS, a trium-
phant return of pallidal stimulation was predicted57. Indeed, there
has been a shift towards implantation of GPi based on
understanding of the outcomes of the VA study11. GPi targeting
increased and was selected for older patients with poorer
cognitive and mood indices58. Our meta-analysis of the literature
shows that this new popularity of GPi as a target has not yet
translated into publications addressing GPi-DBS and justifying
such a gradual shift in patient selection. Future randomized
controlled trials are needed to evaluate the impact on quality of
life when recruiting patients with such selection bias, as surgical
complications increase with age39, depression and cognitive
decline are important determinants of quality of life in PD59,
and a previous study had shown that in PD patients with
preoperatively borderline impaired cognition, STN-DBS did not
provide any benefit in terms of quality of life60.
Even 14 years after the meta-analysis by Kleiner-Fisman et al.10,
which provided the first comprehensive results to estimate the
extent of the effects of STN-DBS in PD, studies reporting the
outcomes for the main indication of DBS, namely motor
fluctuations and dyskinesias, are still very heterogeneous, due to
missing reporting or more importantly, different evaluation tools
(UPDRS items in different combinations, different specific rating
scales, or patient diaries). As a result, the available and comparable
data are limited, especially with regard to dyskinesia, and, at least
in the context of our analysis, only allow a comparison of
percentage changes in different specific total dyskinesia scores,
but not of dyskinesia severity or dyskinesia duration only. This
highlights the urgent need for a uniform and more detailed
assessment of these motor complications across centers. On
average, dyskinesia and daily OFF time were significantly
improved by STN stimulation (62.5% decrease in dyskinesia, n=
950; 69.1% decrease of OFF time), whereas the available data for
GPi-DBS was not sufficient for a comprehensive analysis, but at
least showed a weighted mean improvement of 39.7%. In
contrast, change in UPDRS-III scores in the stimulation-ON/
medication-OFF condition compared to the baseline medication-
OFF condition is available throughout almost all publications and
therefore still the most commonly used measure to assess DBS
efficacy. On average, there was a convincing improvement in
UPDRS-III scores by STN- and GPi-DBS compared to preoperative
baseline. Although we have not conducted a comparative analysis
of these two targets and the discrepant counts of STN and GPi
studies affects the precision of our estimates, the improvement in
motor symptoms (UPDRS-III) of 50.5% for STN-DBS versus 29.8%
for GPi-DBS suggests that STN-DBS is superior to GPi-DBS in terms
of motor outcomes.
Fig. 7 Change in total PDQ-39 summary index (SI) score following STN-DBS. Postoperative vs. preoperative state: PDQ-39 (SI) Mean
Difference. N= number of subjects at follow-up; FU= follow-up time; CI= confidence interval; RE Model= random-effects model.
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Interestingly, despite technical advances, STN studies showed a
slightly lower response to DBS in the period 2005–2019 compared
with the period 1993–2004 covered by Kleiner-Fisman et al.10,
which may be due to the fact that subjects enrolled in the studies
since 2005 had a shorter disease duration and were less affected
in terms of UPDRS-II and -III. In addition, this may also be
explained by the fact, that the technical achievements in imaging,
targeting, and intraoperative procedures have not yet translated
into a relevant advantage over the reviewed period, as they have
not all been consistently used by all centers.
The question of the optimal DBS target in PD may not be
sufficiently clarified with the UPDRS-III medication OFF score as
the primary endpoint, because it does not take into account non-
motor symptoms. Results of the two target structures are also
difficult to compare, as both targets require very different
postoperative management. A relevant LEDD reduction is only
possible with STN-DBS and also mandatory to reduce dyskinesia.
This, in turn, can lead to apathy and dopamine withdrawal
syndrome on one side, or to an improvement of impulse control
disorders on the other side with a major impact on quality of life61.
Therefore, quality of life assessed by the PDQ-39 may be more
appropriate to assess DBS efficacy, as this outcome measure is
affected not only by changes in motor symptoms but also by
changes in non-motor symptoms and motor complications. For
this reason, QOL measurement was introduced in DBS62 and was
chosen as the main outcome criterion in the very first randomized
controlled trial on DBS13. Our meta-analysis showed a moderate
improvement in quality of life (PDQ-39) of approximately 22%
with STN-DBS, while the information for GPi was not sufficient for
analysis. Although there were only a few STN studies (n= 11) with
high variance of results, this improvement is clinically highly
relevant, when considering that patients with best medical
treatment tend to worsen their quality of life over the same
period61. Activities of daily living (UPDRS-II) as a main determinant
of quality of life improved on average by 47% after STN surgery,
while the GPi studies showed a lower improvement of 18.5%.
However, due to the relatively few GPi studies that qualified for
analysis, this finding must be interpreted with caution, in
particular considering the fact that three years after DBS surgery
there was no difference in long-term results between STN and GPi
with regard to quality of life63–65.
Overall, the published studies are heterogeneous, especially
regarding the (primary) outcome parameters, the assessment
tools used, and the selection criteria for DBS, which can certainly
be explained in part by our inclusion criteria and the inclusion of
small non-randomized open-label studies. However, this hetero-
geneity also affects the RCTs as there are differences in the choice
of primary outcome parameters, partly due to the different
requirements of the regulatory authorities in the United States
and Europe. Furthermore, patient selection is not identical as far as
levodopa-sensitivity is concerned (Fig. 4). Postoperative manage-
ment can be impacted by differences in healthcare systems, which
can determine whether DBS is managed on an outpatient or an in-
hospital basis with consequences on potential expert time
devoted to an individual patient. Therefore, we believe that this
heterogeneity reflects clinical reality. Many questions including
target preference (STN vs GPi) could not be solved so far by
randomized controlled trials, which did not come to identical
conclusions11,18, resulting in DBS targeting (STN vs GPi) based on
experience of a team, differences in health care systems, and
analysis of the full literature, rather than just evidence-based
medicine. Therefore, our meta-analysis highlights the need to
identify predictors of motor and non-motor outcomes or to
investigate the impact of new techniques, such as the advent of
newer imaging and targeting techniques, MRI-guided asleep DBS,
current steering, or closed loop DBS. To address such knowledge
gaps, the use of prospective registries with targeted data
collection in the pre-operative, operative, and post-operative
phases of DBS treatment66 may be a good option providing larger
data allowing for more detailed analyses67.
Although the efficacy of DBS for the treatment of PD is well
recognized, preoperative predictive factors for a favorable out-
come of DBS are still not sufficiently known. In accordance with
Kleiner-Fisman et al.10, the preoperative L-dopa responsiveness
was highly predictive of the motor outcome of STN-DBS (Pearson
P= 0.00001). From our correlation analysis, the average disease
duration prior to implantation appears to be influencing the
quality of the prediction made by pre-operative-L-dopa challenge
for the benefit of STN-DBS (P= 0.003). The longer the patient is
suffering from PD before the implantation, the more the
prediction made by pre-operative L-dopa response will corre-
spond to the possible improvement caused by STN-DBS. Motor
fluctuations, as measured by the MDS-UPDRS during the L-dopa
challenge, depend on fluctuations in dopamine concentration in
the nigro-striatal dopaminergic synapse that increase over time
due to progressive degeneration of dopaminergic nigral neu-
rons68. The prominent on–off fluctuations in later disease stages
with severe degeneration are good predictors of DBS out-
come69,70. In earlier disease stages with partially preserved
dopamine buffering function of presynaptic neurons, prediction
of potential benefit based on L-dopa challenge might be less
reliable because of the more erratic wearing-off. This should be
kept in mind when discussing DBS in patients with earlier disease
stages and less pronounced motor fluctuations. In these patients,
long-acting dopamine agonists may mask the true severity of
untreated parkinsonism and should therefore be discontinued
several days before the L-dopa challenge. This strategy was
successfully used in the EARLYSTIM trial17, and based on this
experience, we would recommend such an approach on an
individual basis closely monitoring the patients in order to prevent
dopamine agonist withdrawal syndrome71. Yet the poor fit of the
linear regression shows that average disease duration is not the
only factor influencing the prediction quality. It is highly likely that
other unmeasured factors or unpublished data such as electrode
placement or unmeasurable factors such as comorbidity also
influence the quality of the prediction made by pre-operative-L-
dopa challenge for the benefit of STN-DBS. Although there may be
less certainty about the predictive power of the preoperative
levodopa response for the benefit of STN-DBS in patients with
early disease stage, the degree of motor and quality of life benefits
in these patients is comparable17. For this reason, and as there is
no loss of efficacy reported for STN-DBS in the very long term72,
we would recommend STN-DBS in the presence of motor
complications in early disease stages.
The median proportion of all surgery-related intracranial
bleeding (ICH) for both targets together and regardless of whether
symptomatic or not, was 3.1% in our review and 1.65% for
symptomatic bleeding with permanent consequences, which is
within the published ICH incidence range of 1.2–5.0%73. Almost
exclusively in STN studies, an additional distinction was made
between ICH with transient deficits (1.0%) and asymptomatic
(2.1%) ICH, with the latter only documented in a few studies.
Surgery-related infection was the most frequent complication of
DBS with a median proportion of 5.1%. In the literature,
frequencies of infectious complications have been reported in a
range between 0 and 15%73–75, but this variation is likely due to
the different definitions of a postoperative infection across centers.
Overall, the analysis of AE revealed an inconsistent and non-
systematic reporting across study centers and highlights the
urgent need for a uniform recording with unambiguous categories
as already proposed by others74.
A limitation of this review is that due to the substantial
numerical discrepancies between STN and GPi studies a compara-
tive analysis between these two targets was not possible. In
addition, a detailed analysis of motor complications as well as
other individual variables such as surgical techniques, patient
M.L. Lachenmayer et al.
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selection, and the quality of postoperative management was also
not possible due to the lack of reporting or differences in the used
assessment tools across centers. Nevertheless, by including also
non-randomized open studies we maximized the number of
studies and subjects to avoid bias and also enabled the analysis of
other variables such as quality of life compared to previous meta-
analyses.
In summary, DBS is an established and effective treatment for
levodopa-responsive PD. While in the early days of DBS contrast
ventriculography and multichannel microelectrode recording (MER)
were mandatory for successful targeting, advances in imaging have
now made it possible to achieve good clinical results with DBS even
without MER76. Although our meta-analysis does not allow us to
distinguish between the influences of the many individual variables
of surgical techniques, patient selection, and the quality of
postoperative management, it is rather surprising that the recent
very convincing results of modern surgery with its technological
advances77 are still comparable to the efficacy and safety results of
the pioneering team from Grenoble3.
To conclude, the numerical predominance of the STN studies
compared to GPi studies clearly indicates that the STN has
become the preferred target for the treatment of levodopa-
responsive PD.
METHODS
Literature search and selection of articles
A comprehensive review of the literature from 1990 until August 2019 was
conducted using PubMed database. Search terms included “deep brain
stimulation, “neurostimulation” “Parkinson’s disease,” “subthalamic
nucleus,” “globus pallidus pars interna”. The search string excluded
reviews, meta-analyses, and case reports. The search was limited to
articles in English language. This systematic review process and meta-
analysis was performed as outlined in the PRISMA Statement (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)78. Retrieved
abstracts were reviewed, and distinct inclusion criteria were applied to the
selection of articles for effectiveness and safety analysis. For the efficacy
analysis, abstracts were scrutinized to include only articles with a minimum
of 10 subjects reporting Unified Parkinson’s Disease Rating Scale (UPDRS)
III scores at baseline and follow-up (between 6 months and 12 months
after the implantation of the DBS electrodes). For more detailed
information on search and selection criteria see supplementary material.
After the initial review process five additional studies3,11,17,26,36 of seminal
contribution to the clinical field of the present review were identified by
the authors (P.K. and L.L) and added to the analysis, even though they did
not fully comply with the search criteria as defined above. For a more
detailed specification see supplementary material.
Data extraction
The following key study characteristics and patients’ demographics were
extracted: name of first author, publication year, enrollment start, and
study sample size, therapeutic target location, mean age at surgery, mean
disease duration, and pre-operative levodopa responsiveness. Clinical data
reported before and after surgery on following variables were retrieved
from the selected articles: UPDRS-II and -III score, Levodopa Equivalent
Daily Dose (LEDD), dyskinesia severity, mean daily OFF time, and
Parkinson’s Disease Questionnaire summary index (PDQ-39 SI). Preopera-
tive L-dopa responsiveness (% difference between mean preoperative
medication-OFF UPDRS-III score and mean medication-ON UPDRS-III score)
and postoperative response to DBS (% difference between mean
preoperative medications-OFF UPDRS-III score and mean postoperative
medication-OFF/stimulation-ON UPDRS-III score) were calculated. The
UPDRS-III score from the 6- or 12-month post-operation time points
(except for Follett et al.11 and Schuepbach et al.17 for which 24-month time
point was selected) was used as the postoperative UPDRS-III score. Data
were aggregated regarding the different outcomes. Furthermore, a surgical
efficiency index was defined
surgical efficiency ¼ Postoperative stimulation induced improvement
Preoperative Levodopa induced improvement
For the safety analysis, the adverse events (AE) were listed if reported in
at least 4 studies and were classified as surgery-related, hardware-related,
an interaction of body and hardware, or in subcategories of stimulation-
induced effects.
Statistical analysis
Heterogeneity of the datasets to be analyzed was evaluated through both
Cochran’s Q79 and Higgins I2 tests80 for the sake of relevance. Based on
heterogeneity and the sample size of datasets, restricted maximum
likelihood estimates of change in absolute scores/dose or percentage-of-
score/dose-at-baseline after surgery (difference between postoperative
stimulation-ON/medication-OFF and preoperative medication-OFF condi-
tion) were generated using the random-effects model, as suggested by
Jackson and colleagues81.
The presence of bias was explored graphically by constructing funnel
plots, with estimates of surgery effect per study plotted against the
standard errors associated with these estimates. Furthermore, statistically
significant evidence of bias was sought using Egger’s regression test82.
For STN-DBS, sample size allowed for the analysis of the influence of
available baseline variables such as average disease duration, average age
at implantation, UPDRS-II and -III scores, PDQ-39 SI, publication year,
enrollment start, LEDD, and L-dopa responsiveness on the predictive
power of preoperative L-dopa responsiveness at baseline. Normality of the
distribution of datasets collected for the variables was verified through a
Shapiro–Wilk test. Correlation of each dataset with the surgical efficiency
index was evaluated using Pearson’s test when both datasets followed a
normal distribution or Spearman’s test when one of the datasets was not
following a normal distribution.
The readxl83 and metafor84 libraries were used within the R project
v3.6.185 (extended with RStudio v1.1.463 GUI) for statistical analysis. The
Fiji86 software was used for linear estimation of scores on plots of
publications.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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